Delcath Systems Inc
NASDAQ:DCTH

Watchlist Manager
Delcath Systems Inc Logo
Delcath Systems Inc
NASDAQ:DCTH
Watchlist
Price: 11.19 USD -2.19%
Market Cap: 357.7m USD
Have any thoughts about
Delcath Systems Inc?
Write Note

Delcath Systems Inc
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Delcath Systems Inc
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Delcath Systems Inc
NASDAQ:DCTH
Operating Expenses
-$45.2m
CAGR 3-Years
-17%
CAGR 5-Years
-13%
CAGR 10-Years
-7%
Becton Dickinson and Co
NYSE:BDX
Operating Expenses
-$6.3B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
-9%
Boston Scientific Corp
NYSE:BSX
Operating Expenses
-$8.1B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
Stryker Corp
NYSE:SYK
Operating Expenses
-$9.2B
CAGR 3-Years
-8%
CAGR 5-Years
-8%
CAGR 10-Years
-9%
Abbott Laboratories
NYSE:ABT
Operating Expenses
-$16B
CAGR 3-Years
-1%
CAGR 5-Years
-3%
CAGR 10-Years
-7%
Intuitive Surgical Inc
NASDAQ:ISRG
Operating Expenses
-$3.2B
CAGR 3-Years
-17%
CAGR 5-Years
-14%
CAGR 10-Years
-14%
No Stocks Found

Delcath Systems Inc
Glance View

Market Cap
357.7m USD
Industry
Health Care

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.

DCTH Intrinsic Value
12.95 USD
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Delcath Systems Inc's Operating Expenses?
Operating Expenses
-45.2m USD

Based on the financial report for Sep 30, 2024, Delcath Systems Inc's Operating Expenses amounts to -45.2m USD.

What is Delcath Systems Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-7%

Over the last year, the Operating Expenses growth was -19%. The average annual Operating Expenses growth rates for Delcath Systems Inc have been -17% over the past three years , -13% over the past five years , and -7% over the past ten years .

Back to Top